Unum Therapeutics Inc (UMRX) Expected to Announce Quarterly Sales of $2.45 Million

Share on StockTwits

Wall Street analysts expect that Unum Therapeutics Inc (NASDAQ:UMRX) will post sales of $2.45 million for the current quarter, according to Zacks Investment Research. Two analysts have made estimates for Unum Therapeutics’ earnings, with estimates ranging from $2.40 million to $2.50 million. The business is expected to issue its next earnings results on Monday, August 13th.

According to Zacks, analysts expect that Unum Therapeutics will report full year sales of $9.57 million for the current financial year, with estimates ranging from $9.42 million to $9.70 million. For the next financial year, analysts expect that the company will report sales of $15.07 million per share, with estimates ranging from $10.00 million to $17.62 million. Zacks’ sales calculations are a mean average based on a survey of sell-side research analysts that that provide coverage for Unum Therapeutics.

Unum Therapeutics (NASDAQ:UMRX) last issued its earnings results on Monday, May 14th. The company reported ($0.66) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.35) by ($0.31). The company had revenue of $2.22 million for the quarter, compared to analysts’ expectations of $2.45 million.

UMRX has been the subject of a number of research reports. Morgan Stanley initiated coverage on shares of Unum Therapeutics in a report on Monday, April 23rd. They set an “overweight” rating and a $20.00 target price for the company. Wedbush initiated coverage on shares of Unum Therapeutics in a report on Monday, April 23rd. They set an “outperform” rating and a $18.00 target price for the company. SunTrust Banks initiated coverage on shares of Unum Therapeutics in a report on Monday, April 23rd. They set a “buy” rating and a $21.00 target price for the company. Finally, Cowen initiated coverage on shares of Unum Therapeutics in a report on Monday, April 23rd. They set a “market perform” rating for the company.

A number of large investors have recently modified their holdings of the stock. Millennium Management LLC bought a new stake in Unum Therapeutics during the first quarter worth approximately $982,000. Highland Capital Management LP acquired a new position in Unum Therapeutics in the 1st quarter worth approximately $770,000. Point72 Asset Management L.P. acquired a new position in Unum Therapeutics in the 1st quarter worth approximately $3,599,000. Sabby Management LLC acquired a new position in Unum Therapeutics in the 1st quarter worth approximately $2,917,000. Finally, Platinum Investment Management Ltd. acquired a new position in Unum Therapeutics in the 1st quarter worth approximately $2,499,000. Hedge funds and other institutional investors own 48.30% of the company’s stock.

Shares of NASDAQ:UMRX opened at $14.59 on Tuesday. Unum Therapeutics has a 1-year low of $10.15 and a 1-year high of $16.20.

Unum Therapeutics Company Profile

Unum Therapeutics Inc, a clinical stage biopharmaceutical company, develops and commercializes immunotherapy products designed to harness the power of a patient's immune system to cure cancer. Its lead product candidate is the ACTR087 used in combination with rituximab, which is in Phase I clinical trials to treat adult patients with relapsed or refractory non-Hodgkin lymphoma.

Get a free copy of the Zacks research report on Unum Therapeutics (UMRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Unum Therapeutics (NASDAQ:UMRX)

Receive News & Ratings for Unum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Unum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply